Literature DB >> 6404327

Lineage infidelity in acute leukemia.

L J Smith, J E Curtis, H A Messner, J S Senn, H Furthmayr, E A McCulloch.   

Abstract

Blast cells from 20 patients with acute leukemia (13 diagnosed myeloblastic and 7 as lymphoblastic, using the FAB classification) were studied using antibodies to lineage-specific differentiation markers. The phenotypic findings were usually consistent with the clinical diagnosis. However, examples were encountered where individual blast cells had a cytoplasmic marker of one lineage and a surface marker of a different lineage (lineage infidelity). Six examples of intramyeloid (two different myeloid lineages in the same cell) and three examples of interlineage infidelity (myeloid and lymphoid markers in the same blast cell) were encountered. No doubly marked cells were found in control material consisting of normal marrow cells, marrow regenerating after transplantation, or multilineage colonies derived from marrow in culture. A significant trend was observed relating the presence of lineage infidelity and failure of remission-induction. The data are interpreted as support for abnormal gene expression in leukemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404327

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Configuration of immunoglobulin and T cell receptor beta and gamma genes in acute myeloid leukaemia: pitfalls in the analysis of 40 cases.

Authors:  L Parreira; C Carvalho; H Moura; A Melo; P Santos; J E Guimarães; A Parreira
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

Review 3.  A classification of acute leukaemia for the 1990s.

Authors:  D Catovsky; E Matutes; V Buccheri; V Shetty; J Hanslip; N Yoshida; R Morilla
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

4.  Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia.

Authors:  Satoko Oka; Taiji Yokote; Toshikazu Akioka; Satoshi Hara; Kichinosuke Kobayashi; Yuji Hirata; Nobuya Hiraoka; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

5.  Acute leukemia expressing the gamma gene product of the putative second T cell receptor.

Authors:  R González-Sarmiento; T W LeBien; J G Bradley; J M Greenberg; J G Seidman; S Ang; J H Kersey
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

6.  Effect of differentiation on the leucine enkephalin-degrading soluble enzymes released by the K562(S) cell line.

Authors:  M Marini; L Bongiorno; A Urbani; E Trani; L G Roda
Journal:  Neurochem Res       Date:  1997-12       Impact factor: 3.996

7.  Biphenotypic leukaemia: a case of mixed T lymphoblastic and myeloblastic leukaemia.

Authors:  M A Morgan; C S Scott; J Tavares de Castro; H J Limbert; N Polli; D Catovsky; R D Pyrah; B E Roberts
Journal:  J Clin Pathol       Date:  1985-05       Impact factor: 3.411

8.  The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations.

Authors:  Brenton T Tan; Roger A Warnke; Daniel A Arber
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

9.  Establishment of the DU.528 human lymphohemopoietic stem cell line.

Authors:  J Kurtzberg; S H Bigner; M S Hershfield
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

10.  Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome.

Authors:  Bharat Bhushan; Pradeep Singh Chauhan; Sumita Saluja; Saurabh Verma; Ashwani Kumar Mishra; Saeed Siddiqui; Sujala Kapur
Journal:  Clin Exp Med       Date:  2009-09-25       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.